Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 4:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 593 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: PRIME Clear all
Recruiting Phase 1 Interventional

KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer

NCT06411691
View directory record Official record
Conditions
Colorectal Cancer, Pancreatic Cancer
Interventions
KRAS Vaccine with Poly-ICLC adjuvant, Balstilimab, Botensilimab
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 23, 2026, 4:44 AM EDT
Not yet recruiting Not applicable Interventional

Effectiveness of Artificial-Intelligence (AI) Bolus Priming Added to an Existing Fully Automated Control Algorithm (AIDANET)

NCT07517770
View directory record Official record
Conditions
Type 1 Diabetes Mellitis
Interventions
Hybrid Closed Loop (HCL) x 2 weeks, AIDANET x 2 weeks, AIDANET AI x 4 weeks
Device
Lead sponsor
Sue Brown
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 23, 2026, 4:44 AM EDT
Completed Phase 4 Interventional Results available

The Study of Exenatide Action on Vessel Function in Type 2 Diabetes and Prediabetes

NCT01181986
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Exenatide SC, Exenatide IV, Placebo SC, Exendin-9, Placebo IV
Drug
Lead sponsor
Carl T. Hayden VA Medical Center
Federal
Eligibility
35 Years to 70 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated May 20, 2014 · Synced Oct 23, 2026, 4:44 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

COVID-19 Oral and Subcutaneous Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenovirus Platform in Healthy Volunteers in USA

NCT04732468
View directory record Official record
Conditions
Covid19
Interventions
hAd5-S-Fusion+N-ETSD (Suspension for injection), hAd5-SFusion+ N-ETSD (Oral capsule)
Biological · Drug
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
2
States / cities
El Segundo, California • Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 23, 2026, 4:44 AM EDT
Terminated Phase 2 Interventional Results available

Translating Neuroprediction Into Precision Medicine Via Brain Priming

NCT03370510
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Oxytocin, Pivotal Response Treatment, Placebo
Drug · Behavioral
Lead sponsor
Yale University
Other
Eligibility
5 Years to 9 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 9, 2022 · Synced Oct 23, 2026, 4:44 AM EDT
Completed Phase 2 Interventional Results available

Web-based Interpretation Training For Anxiety

NCT02382003
View directory record Official record
Conditions
Anxiety
Interventions
Positive Cognitive Bias Modification - Interpretation, 50/50 Cognitive Bias Modification - Interpretation, Anxious Imagery Prime, Neutral Imagery Prime
Behavioral
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
807 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 20, 2025 · Synced Oct 23, 2026, 4:44 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Test the Safety of Three Experimental HIV Vaccines

NCT00000946
View directory record Official record
Conditions
HIV Infections, HIV Seronegativity
Interventions
HIV p24/MF59 Vaccine, ALVAC-HIV MN120TMG (vCP205), ALVAC-RG Rabies Glycoprotein (vCP65), rgp120/HIV-1 SF-2
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2001
U.S. locations
7
States / cities
Birmingham, Alabama • Baltimore, Maryland • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 23, 2026, 4:44 AM EDT
Terminated Not applicable Interventional

G-CSF-Treated Donor Bone Marrow Transplant in Treating Patients With Hematologic Disorders

NCT00253552
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Sarcoma
Interventions
filgrastim, busulfan, cyclophosphamide, cyclosporine, etoposide, methotrexate, allogeneic bone marrow transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
Up to 24 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 28, 2012 · Synced Oct 23, 2026, 4:44 AM EDT
Completed Phase 1Phase 2 Interventional Results available

First-in-Human, Phase 1b/2a Trial of a Multipeptide Therapeutic Vaccine in Patients With Progressive Glioblastoma

NCT04116658
View directory record Official record
Conditions
Glioblastoma, Adult
Interventions
Multiple dose of EO2401
Biological
Lead sponsor
Enterome
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 28, 2025 · Synced Oct 23, 2026, 4:44 AM EDT
Recruiting Not applicable Interventional

DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics

NCT06296368
View directory record Official record
Conditions
Hematologic Malignancies, Lymphoma, Multiple Myeloma, Leukemia, Blood Cancers
Interventions
Preference Reporting to Improve Management and Experience (PRIME)
Behavioral
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
60 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 23, 2026, 4:44 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Trial to Evaluate the Safety and Immunogenicity of Priming Regimens of 426c.Mod.Core-C4b and Optional Boost Regimen With HIV Trimer BG505 SOSIP.GT1.1 gp140, Both Adjuvanted With 3M-052-AF + Alum in Healthy, Adult Participants Without HIV

NCT05471076
View directory record Official record
Conditions
HIV-1-infection
Interventions
426c.Mod.Core-C4b 30 mcg, 426c.Mod.Core-C4b 100 mcg, 426c.Mod.Core-C4b 300 mcg, Placebo, BG505
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
6
States / cities
Birmingham, Alabama • San Francisco, California • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 23, 2026, 4:44 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to Polyvalent HIV-1 Vaccine in HIV Uninfected Adults

NCT00061243
View directory record Official record
Conditions
HIV Infections
Interventions
HIV-1 DNA vaccine with protein vaccine boost
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2010
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 26, 2008 · Synced Oct 23, 2026, 4:44 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Combination Listeria/GVAX Immunotherapy in Pancreatic Cancer

NCT01417000
View directory record Official record
Conditions
Metastatic Pancreatic Cancer
Interventions
GVAX Pancreas, CRS-207, Cyclophosphamide
Biological · Drug
Lead sponsor
Aduro Biotech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
10
States / cities
Tampa, Florida • Baltimore, Maryland • Bethesda, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated May 8, 2018 · Synced Oct 23, 2026, 4:44 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Immune Response to an HIV DNA Plasmid Vaccine Prime Followed by Adenovirus Boost in HIV-uninfected Individuals

NCT00955006
View directory record Official record
Conditions
HIV Infections
Interventions
VRC-HIVDNA-016-00-VP, VRCHIVADV014-00-VP
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Oct 23, 2026, 4:44 AM EDT
Recruiting Phase 1 Interventional

MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors

NCT05076760
View directory record Official record
Conditions
Solid Tumor, Advanced Cancer, Metastatic Cancer, Non Small Cell Lung Cancer, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, Melanoma, Pancreatic Cancer, Triple Negative Breast Cancer, Head and Neck Cancer
Interventions
MEM-288 Intratumoral Injection, Nivolumab, Docetaxel
Biological · Drug
Lead sponsor
Memgen, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2031
U.S. locations
2
States / cities
Tampa, Florida • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 23, 2026, 4:44 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

TDENV PIV and LAV Dengue Prime-boost Strategy

NCT02239614
View directory record Official record
Conditions
Dengue
Interventions
TDENV-LAV, TDENV-PIV 4 µg + alum adjuvant
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 49 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 15, 2018 · Synced Oct 23, 2026, 4:44 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

H5N1 Priming and Boosting Strategies

NCT00703053
View directory record Official record
Conditions
Influenza
Interventions
A/Vietnam/1203/04, A/Indonesia/05/05
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
505 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
5
States / cities
Decatur, Georgia • Rochester, Minnesota • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2013 · Synced Oct 23, 2026, 4:44 AM EDT
Recruiting Early Phase 1 Interventional

Personalized Dendritic Cell Vaccine Pilot for High Risk TNBC After Neoadjuvant Therapy

NCT06435351
View directory record Official record
Conditions
Breast Cancer, Triple Negative Breast Cancer
Interventions
Leukapheresis, Dendritic Cell (DC) Vaccine
Procedure · Biological
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 23, 2026, 4:44 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Clinical Trial to Evaluate the Safety and Immunogenicity of a Priming Regimen of 426c.Mod.Core-C4b Followed by HxB2.WT.Core-C4b Boosts, Both Adjuvanted With 3M-052 AF + Alum, in Adult Participants Without HIV and in Overall Good Health

NCT06796686
View directory record Official record
Conditions
HIV
Interventions
426c.Mod.Core-C4b, HxB2.WT.Core-C4b, 3M-052-AF adjuvant, Aluminum hydroxide suspension (Alum) adjuvant, Diluent
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
6
States / cities
San Francisco, California • Atlanta, Georgia • Decatur, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Oct 23, 2026, 4:44 AM EDT
Active, not recruiting No phase listed Observational

Prospective Clinical Evaluation of Posterior Single-tooth Zirconia Ceramic Restorations

NCT07797972
View directory record Official record
Conditions
Dental Crowns
Interventions
IPS e.max® ZirCAD Prime Esthetic
Combination Product
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
40 participants
Timeline
2022 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 23, 2026, 4:44 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Combination Immunotherapy Treatment for Locally Advanced Unresectable or Metastatic, PD-L1 Negative (CPS<10), gBRCA Negative, Triple Negative Breast Cancer Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy

NCT07762703
View directory record Official record
Conditions
Triple-Negative Breast Cancer (TNBC)
Interventions
BreakVax, Ipilimumab 2.5 mg, Pembrolizumab, Standard-of-care chemotherapy, Losartan and aspirin
Drug
Lead sponsor
BreakBio Corp
Industry
Eligibility
18 Years to 72 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 23, 2026, 4:44 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Cannabis' Impact on Alcohol Consumption

NCT05389930
View directory record Official record
Conditions
Alcohol Drinking, Cannabis Use, Cannabis, Alcohol Use Disorder
Interventions
THC-dominant cannabis, CBD-dominant cannabis, Cannabis placebo, Alcohol, Alcohol placebo
Drug
Lead sponsor
Brown University
Other
Eligibility
21 Years to 50 Years
Enrollment
350 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 23, 2026, 4:44 AM EDT
Recruiting Phase 1Phase 2 Interventional

Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)

NCT04715022
View directory record Official record
Conditions
Hypertension, Cardiovascular Diseases
Interventions
Ascorbic acid solution (American Regent Laboratories Inc.), Saline
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
35 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 8, 2025 · Synced Oct 23, 2026, 4:44 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Cancer Preventive Vaccine Nous-209 for Lynch Syndrome Patients

NCT05078866
View directory record Official record
Conditions
Colorectal Carcinoma, Lynch Syndrome
Interventions
Adenoviral Tumor-specific Neoantigen Priming Vaccine GAd-209-FSP, Biospecimen Collection, Endoscopic Biopsy, MVA Tumor-specific Neoantigen Boosting Vaccine MVA-209-FSP, Questionnaire Administration
Biological · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
3
States / cities
Duarte, California • Philadelphia, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Oct 23, 2026, 4:44 AM EDT